Utilizing of Platform Clinical Trial to Help Make Faster Decisions

Slides:



Advertisements
Similar presentations
Accra, Ghana October 19-23, Extending Health Insurance: How to Make It Work DESIGN ELEMENT 8: MONITORING AND EVALUATION OF HEALTH INSURANCE SCHEMES.
Advertisements

Phase II/III Design: Case Study
Mobile Marketing in Practice
© 2005 Prentice Hall, Decision Support Systems and Intelligent Systems, 7th Edition, Turban, Aronson, and Liang 4-1 Chapter 4 Modeling and Analysis Turban,
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Adaptive Designs for Clinical Trials
Are the results valid? Was the validity of the included studies appraised?
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Collaborative Work Package Criteria Suitable for accomplishing in a period of 90 days to 1 year. Work should fall within the expertise of one or more consortium.
Software Project Planning Defining the Project Writing the Software Specification Planning the Development Stages Testing the Software.
Validation / citations. Validation u Expert review of model structure u Expert review of basic code implementation u Reproduce original inputs u Correctly.
SECOND EXPERT MEETING KA1 PROJECT VIENNA MAY 2011 WORKGROUP 2 PROFESSIONAL DEVELOPMENT INTERIM REPORT.
Regulatory Affairs and Adaptive Designs Greg Enas, PhD, RAC Director, Endocrinology/Metabolism US Regulatory Affairs Eli Lilly and Company.
Sample Size Determination
Project Planning Defining the project Software specification Development stages Software testing.
PRAGMATIC Study Designs: Elderly Cancer Trials
Microsoft Cloud Adoption Framework Foundation
Introduction to Marketing Research
June 29, 2017 Suzanne Hendrix, PhD Pentara Corp
M&E Workshop for Full Proposal
Sample Size Determination
Monitoring and Evaluation: A Review of Terms
Critically Appraising a Medical Journal Article
A new platform for testing TSO-DSO coordination schemes
Monitoring and Evaluation Frameworks
5 Different Observational Datasets: Pros & Cons
CLINICAL PROTOCOL DEVELOPMENT
Impact of censoring on the statistical methods for handling non-proportional hazards in Immuno-Oncology studies Yifan Huang, Luping Zhao, Jiabu Ye, and.
GWE Core Grid Wizard Enterprise (
Introduction Purpose Objectives Content Learning Time
Statistical Approaches to Support Device Innovation- FDA View
Supplementary Table 1. PRISMA checklist
Clinical and Fiscal “Cost of Delay” – a statistician’s view
Rui (Sammi) Tang Biostatistics Associate Director, Vertex
S1400 OVERVIEW / BACKGROUND
Purpose of Critical Appraisal
Graduation Project Kick-off presentation - SET
Copyright 2012 John Wiley & Sons, Inc. Chapter 7 Budgeting: Estimating Costs and Risks.
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Statistical Computation Tools in Pharmaceutical Drug Development and Manufacturing Life Cycle Fasheng Li Ke Wang Pharmaceutical Statistics Worldwide.
Increased Efficiency and Effectiveness
S1316 analysis details Garnet Anderson Katie Arnold
Dose-finding designs incorporating toxicity data from multiple treatment cycles and continuous efficacy outcome Sumithra J. Mandrekar Mayo Clinic Invited.
Pilot Studies: What we need to know
Issues in Hypothesis Testing in the Context of Extrapolation
Software engineering -1
Practical Software Engineering
An Introduction to Software Architecture
Bob Friedman, Xybion; Anthony Fata, SNBL
GWAS/QTL Apps Overview
#GCDigital Design System
Computer Graphics Graphics Hardware
Design Brief.
The Hub Innovation Program Evaluation Plan
Module 5: Formulating Research Questions
Jennifer Gauvin, Group Head and Director
CAD DESK PRIMAVERA PRESENTATION.
European Prevention Alzheimer’s Dementia
Optimal Basket Designs for Efficacy Screening with Cherry-Picking
The 3rd Stat4Onc Annual Symposium
Systematic review of atopic dermatitis disease definition in studies using routinely-collected health data M.P. Dizon, A.M. Yu, R.K. Singh, J. Wan, M-M.
Module 1.1 Overview of Master Facility Lists in Nigeria
A response-adaptive platform trial may start by enrolling a broad patient population and randomise patients equally across a range of treatments, shown.
M & E Plans and Frameworks
Joint Statistical Meeting 2019 J. Kyle Wathen Director
Quantitative Decision Making (QDM) in Phase I/II studies
David Manner JSM Presentation July 29, 2019
Finding a Balance of Synergy and Flexibility in Master Protocols
Quantitative Decision Making (QDM) in Phase I/II studies
Students Opportunities: Conferences:
Presentation transcript:

Utilizing of Platform Clinical Trial to Help Make Faster Decisions ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop J. Kyle Wathen Director Statistical Modeling and Methodology

Outline Very brief introduction to platform trials Bayesian decision framework Package website Future plans

Platform Trial - Introduction An experimental infrastructure to evaluate multiple treatments and/or combinations of treatments in heterogeneous patient populations. Not all interventions are included, or even known, at the start of the platform Utilize a Master Protocol – no compound specifics New compounds are added with an Intervention Specific Appendix (ISA) - details about the compound Key benefits include – improvements in patient recruitment and borrowing of patient data across ISAs

Typical Timeline - POC Jan 2020 Start Platform Jan 2022 Jan 2024 Compound 5 Compound 4 Compound 3 Compound 2 Compound 1 Jan 2020 Start Platform Jan 2022 Jan 2024 Jan 2026

Sharing Information Between ISAs Start Platform 5

Sharing Information Between ISAs Start Platform 6

Sharing Information Between ISAs Start Platform 7

Sharing Information Between ISAs Start Platform 8

Design and Simulation Many similarities between ISAs Each ISA may require different designs, eg single vs multiple doses One ISA can impact another Recruitment Placebo/Control sharing ISAs may be concurrent or consecutive Currently no commercial software or package that can accomplish all of the requirements Started with R code for first platform trial then extended and started a package in R for the second platform

Bayesian Go-No Go Decision Rules Dual Criteria for each Outcome MAV – Minimum Acceptable Value, TV Target Value mP, mE parameter of interest for P and E, respectively Calculations Pr( d = mP - mE > MAV | data ) > LB Pr(d = mP - mE > TV| data ) > UB Cutoffs: LB, UB   Pr(d > MAV | data ) ≥ LB Pr(d > MAV | data ) < LB Pr(d > TV | data ) ≥ UB Graduate Indeterminate/Continue Pr(d > TV | data ) < UB Drop

Pr(d > MAV | data ) < 0.9 Decision Making Pr( d > MAV | Data ) Pr( d > TV | Data )   Pr(d > MAV | data ) ≥ 0.9 Pr(d > MAV | data ) < 0.9 Pr(d > TV | data ) ≥ 0.05 Graduate Indeterminate/Continue Pr(d > TV | data ) < 0.05 Drop

Combining Outcomes Design 1 Design 2 Outcome 1 Outcome 1 Outcome 2 Graduate Continue Drop Graduate Continue Drop Outcome 2 Outcome 2

Why R Package for Platform Simulation? OCTOPUS – Optimize Clinical Trials on Platforms Using Simulation Not all features are available commercially –desire to test and reuse work if possible Having the R source code allows for new options and extensions Transparent to the nature of what is going on in the trial Many statisticians are familiar with R Freely available at https://kwathen.github.io/OCTOPUS

OCTOPUS - Key Features Random or fixed entry times for ISA Each ISA can have different modeling and decisions Information sharing across ISAs, each ISA can be different Monitoring of ISA can be setup as minimum information with subsequent analysis at predetermined interval or the amount of information needed for each interim analysis Flexibility to add new patient simulator, analysis, randomizers, ect Any number of outcomes Some default plots can be created Covariates and subgroup specific decisions is in development

R Package + Project Specific Files Core components Built on generic functions Tested Generalized functions from projects Community driven development in future versions Define trial design element Define simulation design element Define any project specific functions Key Advantages – Tested code, reuse general parts, speed up development, learn across projects, project details remain in the project specific files, extendable, generic concepts can be moved from projects to package

Shiny App Compare Recruitment Quickly compare options of 2 POC vs Platform with 2 ISAs in terms of recruitment Image or graphic goes here

Image or graphic goes here

Conclusion and Future Plans Have had positive feedback from several people on wanting to use the package Have utilized the package to simulate more than 5 platform studies and 3 non-platform Developers guide Task list Streamline the simulation and creation of results for “standard” output Training In person and videos Training for someone use the package and for anyone interested in helping to extend the package

Thank You! Kyle Wathen kwathen@ITS.JNJ.COM

Backup